177 related articles for article (PubMed ID: 17582001)
21. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.
Heideman DA; Steenbergen RD; van der Torre J; Scheffner M; Alemany R; Gerritsen WR; Meijer CJ; Snijders PJ; van Beusechem VW
Mol Ther; 2005 Dec; 12(6):1083-90. PubMed ID: 16085463
[TBL] [Abstract][Full Text] [Related]
23. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
[TBL] [Abstract][Full Text] [Related]
24. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein.
Demeret C; Garcia-Carranca A; Thierry F
Oncogene; 2003 Jan; 22(2):168-75. PubMed ID: 12527886
[TBL] [Abstract][Full Text] [Related]
25. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
26. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
[TBL] [Abstract][Full Text] [Related]
27. Study on the carcinogenic mechanism of human papillomavirus typel6 E7 protein in cervical carcinoma.
Wang P; Peng Z; Wang H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Jun; 14(2):117-20. PubMed ID: 11503038
[TBL] [Abstract][Full Text] [Related]
28. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA.
Wu S; Meng L; Wang S; Wang W; Xi L; Tian X; Chen G; Wu Y; Zhou J; Xu G; Lu Y; Ma D
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2032-7. PubMed ID: 16609012
[TBL] [Abstract][Full Text] [Related]
29. The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism.
Clere N; Bermont L; Fauconnet S; Lascombe I; Saunier M; Vettoretti L; Plissonnier ML; Mougin C
Exp Cell Res; 2007 Sep; 313(15):3239-50. PubMed ID: 17678892
[TBL] [Abstract][Full Text] [Related]
30. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2.
Bhattacharjee B; Sengupta S
Virology; 2006 Oct; 354(2):280-5. PubMed ID: 16905170
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins.
Yugawa T; Kiyono T
Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753
[TBL] [Abstract][Full Text] [Related]
32. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
33. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response.
Pett MR; Herdman MT; Palmer RD; Yeo GS; Shivji MK; Stanley MA; Coleman N
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3822-7. PubMed ID: 16505361
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.
Santin AD; Zhan F; Bignotti E; Siegel ER; Cané S; Bellone S; Palmieri M; Anfossi S; Thomas M; Burnett A; Kay HH; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Virology; 2005 Jan; 331(2):269-91. PubMed ID: 15629771
[TBL] [Abstract][Full Text] [Related]
35. p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and DeltaN isoforms.
Okuyama T; Kurata S; Tomimori Y; Fukunishi N; Sato S; Osada M; Tsukinoki K; Jin HF; Yamashita A; Ito M; Kobayashi S; Hata RI; Ikawa Y; Katoh I
Oncogene; 2008 Jan; 27(3):308-17. PubMed ID: 17637751
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus: E6 and E7 oncogenes.
Boulet G; Horvath C; Vanden Broeck D; Sahebali S; Bogers J
Int J Biochem Cell Biol; 2007; 39(11):2006-11. PubMed ID: 17768080
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence.
Johung K; Goodwin EC; DiMaio D
J Virol; 2007 Mar; 81(5):2102-16. PubMed ID: 17182682
[TBL] [Abstract][Full Text] [Related]
38. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses.
Kuner R; Vogt M; Sultmann H; Buness A; Dymalla S; Bulkescher J; Fellmann M; Butz K; Poustka A; Hoppe-Seyler F
J Mol Med (Berl); 2007 Nov; 85(11):1253-62. PubMed ID: 17589817
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy.
Martin CM; Astbury K; McEvoy L; O'Toole S; Sheils O; O'Leary JJ
Methods Mol Biol; 2009; 511():333-59. PubMed ID: 19347305
[TBL] [Abstract][Full Text] [Related]
40. A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c).
Pang CL; Toh SY; He P; Teissier S; Ben Khalifa Y; Xue Y; Thierry F
Oncogene; 2014 Jul; 33(31):4039-49. PubMed ID: 24141769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
